Phase I Trial Using Proteasome Inhibitor Bortezomib and Concurrent Temozolomide and Radiotherapy for Central Nervous System Malignancies
- 1 June 2009
- journal article
- Published by Elsevier in International Journal of Radiation Oncology*Biology*Physics
- Vol. 74 (2) , 433-439
- https://doi.org/10.1016/j.ijrobp.2008.08.050
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Phase I/II Study of Bortezomib Plus Docetaxel in Patients with Advanced Androgen-Independent Prostate CancerClinical Cancer Research, 2007
- Randomized Phase II Study of Bortezomib Alone and Bortezomib in Combination With Docetaxel in Previously Treated Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2006
- Bortezomib (PS-341) in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group Phase II Trial (S0327)Journal of Thoracic Oncology, 2006
- Bortezomib Plus Docetaxel in Advanced Non-small Cell Lung Cancer and Other Solid Tumors: A Phase I California Cancer Consortium TrialJournal of Thoracic Oncology, 2006
- Bortezomib (VELCADE®) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefitsAnnals of Oncology, 2006
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- In vitro and In vivo Activity of the Nuclear Factor-κB Inhibitor Sulfasalazine in Human GlioblastomasClinical Cancer Research, 2004
- Analysis of the activation status of Akt, NFκB, and Stat3 in human diffuse gliomasLaboratory Investigation, 2004
- Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant gliomaJournal of Neurosurgery, 1989